Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review - Scorecard - MDSpire
Advertisement
Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review
Clinical Scorecard: Therapeutic Outcomes in Advanced Non-Small Cell Lung Cancer Exhibiting High PD-L1 Levels and MET Exon 14 Skipping Mutation: A Case Study on Addressing Immunotherapy Resistance and a Review of Existing Literature
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Care Setting
Oncology clinics specializing in lung cancer treatment with a focus on personalized therapy.
Key Highlights
Sequential therapy may enhance treatment efficacy and restore sensitivity to immunotherapy.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Regular imaging follow-ups (CT or PET scans) to assess treatment response and disease progression.
Risks
Patient & Prescribing Data
Sequential therapy may enhance treatment efficacy and overcome resistance mechanisms, particularly in older patients.
Clinical Best Practices
Utilize a personalized treatment approach based on molecular characteristics, supported by recent studies.
